Prmt2 regulates the lipopolysaccharide-induced responses in lungs and macrophages

Emilie Dalloneau1, Patricia Lopes Pereira, Véronique Brault

  • 1Centre National de la Recherche Scientifique, Institut de Génétique Biologie Moléculaire et Cellulaire, INSERM, Université de Strasbourg, Unité Mixte de Recherche 7104, 67404 Illkirch, France.

Insights

This study reveals that Prmt2 gene dosage influences lung inflammation and airway hyperresponsiveness. Prmt2 acts as a new regulator of the lipopolysaccharide (LPS)-induced inflammatory pathway.

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • Lipopolysaccharide (LPS) stimulation in the lungs triggers inflammation and airway hyperresponsiveness via the Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) pathway.
  • Proinflammatory cytokine expression and neutrophil recruitment are key components of LPS-induced lung responses.
  • Previous observations in a Prmt2-Col6a1 monosomic model suggested dosage-sensitive genes impacting LPS pathways.

Purpose of the Study:

  • To investigate the role of Prmt2 in regulating LPS-induced lung inflammation and airway hyperresponsiveness.
  • To determine if Prmt2 gene dosage affects key inflammatory responses.
  • To elucidate Prmt2's mechanism of action within the NF-κB signaling pathway.

Main Methods:

  • Analysis of LPS-induced lung responses in wild-type and Prmt2-altered mouse models.
  • Assessment of airway hyperresponsiveness, neutrophil recruitment, and proinflammatory cytokine (IL-6, TNF-α) expression.
  • Evaluation of NF-κB nuclear accumulation in stimulated macrophages.

Main Results:

  • Prmt2 gene dosage significantly influences lung airway hyperresponsiveness and neutrophil recruitment following LPS stimulation.
  • Prmt2 levels directly impact the expression of proinflammatory cytokines, including IL-6 and TNF-α.
  • Loss of Prmt2 function alters the nuclear translocation of NF-κB in LPS-stimulated macrophages.

Conclusions:

  • Prmt2 is identified as a novel regulator of LPS-induced lung inflammatory and airway responses.
  • Prmt2 exerts its effects in a dosage-dependent manner.
  • Prmt2 likely modulates these responses by influencing NF-κB nuclear accumulation, thus acting as a new component of the NF-κB pathway.